ERCC1、RRM1蛋白表达与晚期非小细胞肺癌患者含铂类化疗疗效的相关性分析

The relationship between protein expression in ERCC1 and RRM1 and efficacy of Platin-based chemotherapy in advanced stage of non-small cell lung cancer

目的探讨核苷酸切除修复交叉互补基因1(ERCC1)、核苷酸还原酶1(RRM1)蛋白表达与晚期(II-IB～IV)非小细胞肺癌(NSCLC)含铂方案化疗疗效及预后的关系。方法收集初次就诊且经病理组织学确诊,并经影像学检查证实具有可测量病灶的晚期NSCLC患者38例,采用免疫组织化学法检测肺癌组织标本及其相应的24例癌旁正常肺组织标本中ERCC1、RRM1蛋白表达,分析其与化疗疗效及预后的相关性。结果①ERCC1、RRM1在NSCLC组织中的阳性表达率分别为57.9%、60.5%,癌旁正常肺组织阳性表达率均为29.2%,组间比较差异均有统计学意义(P<0.05);②在20例化疗有效的患者中ERCC1、RRM1阳性表达率均为40.0%,18例化疗无效患者中ERCC1、RRM1阳性表达率分别为77.8%、83.3%,组间比较差异亦有统计学意义(P<0.05);③ERCC1阳性表达组中位生存期、1、2年生存率与ERCC1阴性表达组比较差异无统计学意义;RRM1阳性表达组中位生存期、1、2年生存率分别为(8±1.2)个月、36.3%与13.3%,与RRM1阴性表达组比较[中位生存期、1、2年生存率分别为(16±3.3)个月、56.7%和25.6%]差异有统计学意义(P=0.02)。结论 ERCC1、RRM1在晚期NSCLC组织中高表达,在癌旁正常肺组织中低表达,提示ERCC1、RRM1可能参与了非小细胞肺癌的发生。

Objective To explore the relationship between protein expression in ERCC1 and RRM1 and efficacy of Platin - based chemotherapy in advanced stage of non - small cell lung cancer （NSCLC） and prognosis. Methods 38 patients firstly visited doctors were collected between Jan. 2009 and Jun. 2010 in the General Hospital of Ningxia Medical University, and histologically diag- nosed by imaging examination confirmed in advanced stage of NSCLC with measurable lesions. ERCC1 and RRM1 protein expression were detected in lung cancer organization samples and their corresponding 24 cases of cancer and adjacent normal lung tissue specimens by immunohistochemistry assay. The correlation of those with chemotherapy and prognosis was analyzed. Results The positive expres- sion rate of ERCC1 and RRM1 in NSCLC tissues were respectively 57.9% and 60.5%. Positive expression rates of adjacent normal tis- sue both were 29.2%. There were statistically significant in the two groups （P 〈 0.05） ; 20 patients with chemotherapy of ERCC1 and RRM1 positive expression rate both were 40.0%. 18 patients with chemotherapy were not valid of ERCC1 and RRM1 positive expression rates were respectively 77.8% and 83.3%. There were statistically significant in the two groups （P 〈 0.05 ） ; There was no significant difference of the median survival time, one and two -year survival rate in ERCC1 -positive expression group and ERCC1 -negative ex- pression group. Median survival time, one and two -year survival rates （8 ~ 1.2 ）months in RRM1 positive expression group were re- spectively 36.3% and 13.3%, compared with RRM1 negative expression group （median survival time, one and two -year survival rates （16 ~ 3.3 months） were respectively 56. 7% and 25.6%, and there was significantly different （X2 = 5. 900, P = 0. 015）. Conclusion ERCC1 and RRM1 are highly expressed in advanced stage NSCLC, but low expression in adjacent normal lung tissue. It indicates that ERCC1, RRM1 may be involved in non - small cell lung cancer.